A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
Status:
Completed
Trial end date:
2021-06-03
Target enrollment:
Participant gender:
Summary
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and
pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with
schizophrenia.